ArticleJournal of veterinary science2025
Comparison of pharmacokinetic and pharmacodynamic properties of allopurinol and benzbromarone in a quail model of hyperuricemia.
Article in Journal of veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
importanceHyperuricemia (HUA) is a major metabolic disorder in poultry, leading to gout and kidney damage, which affects farm productivity. Accordingly, understanding the pharmacodynamics (PD) and pharmacokinetics (PK) of uric acid-lowering drugs is essential for improving the treatment strategies in poultry.
objectiveThis study examined the PD and PK characteristics of allopurinol and benzbromarone, two uric acid-lowering drugs, in a quail model of HUA.
methodsA hyperuricemic quail model was established using a high-purine diet. Allopurinol and benzbromarone were administered orally. Blood samples were taken and analyzed for the drug concentrations using high-performance liquid chromatography. Pathological examinations were conducted to assess kidney damage.
resultsBoth drugs lowered the serum uric acid levels. On the other hand, the allopurinol treatment exhibited lower urea and creatinine levels than benzbromarone, indicating potential advantages in reducing kidney damage. Consistent with these findings, the pathological examinations revealed more pronounced kidney damage in the benzbromarone-treated group than in the allopurinol group. PK analysis showed that allopurinol exhibited faster absorption and elimination kinetics than benzbromarone. Both drugs showed a wide distribution in various tissues, with allopurinol and its active metabolite displaying higher excretion levels. CONCLUSIONS AND RELEVANCE: This paper reports the absorption, distribution, metabolism, and excretion processes of allopurinol and benzbromarone in a quail model of HUA. These findings help better understand the PK characteristics of these drugs and promote the use of high uric acid therapy in poultry. In addition, this quail model is a valuable tool for future research on HUA and drug interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.